ASCENTAGE PHARMA GROUP (HKEX: 06855) has announced the issuance of new restricted share units. According to the company's filing, a total of 440,700 restricted share units were granted under its 2021 plan as of the date of the announcement.

These units, equivalent to 440,700 shares, were awarded to 453 selected participants under the 2021 plan, all of whom are employees of the group. This grant is referred to as the 2021 award.

In a separate allocation, the company has also granted 3,223,700 restricted share units under its 2022 plan. This award, equivalent to 3,223,700 shares, was distributed to 251 selected participants. The breakdown of the 2022 award is as follows: two non-executive directors, Dr. Wang Shaomeng and Dr. Lv Dazhong, received 31,858 units; six independent non-executive directors—Mr. Ye Changqing, Mr. Ren Wei, Dr. David Sidransky, Ms. Marina S. Bozilenko, Dr. Debra Yu, and Dr. Marc E. Lippman—received 106,194 units; one senior management member of the company received 150,739 units; 241 other 2022 participants who are group employees received 2,924,900 units; and one service provider, a consultant specializing in R&D and clinical trials, received 10,000 units.

Additionally, the company reported the grant of share options. As of the announcement date, 690,000 share options were issued to 30 grantees under the post-IPO share option scheme. These options entitle the holders to subscribe for a total of 690,000 ordinary shares of the company upon exercise, subject to acceptance by the grantees. The allocation of these options mirrors the structure of the 2022 restricted share unit grant: 31,858 options were granted to the two non-executive directors; 106,194 options to the six independent non-executive directors; 50,641 options to one senior management member; and 501,400 options to 21 other grantees who are group employees.